“Stage IV needs more. Clinical trials require a lot of for doctors & researchers to put together. Any donation is appreciated.” – Amy, a #breastcancer patient at Dana-Farber

This #BreastCancerAwarenessMonth , we are grateful to patients like Amy for sharing with our community. 🤍

We were delighted to welcome Dr. Bora Lim Bora Lim, MD from Baylor Dan L Duncan Comprehensive Cancer Center to be our speaker of the Susan E. Donelan IBC Hope for the Future Lecture Dana-Farber IBC Program. Thank you Dr. Lim for sharing your insights about the role of tumor emboli in the complex biology of IBC.

Sara Tolaney, MD, MPH discusses sacituzumab govitecan in HR+/ HER2– metastatic breast cancer with Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD. #bcsm | Sara Tolaney Martin Dietrich, MD, PhD Gregory Vidal

ow.ly/s0GA50Lh4sr

Thank you ACIR for covering this conference and my talk. I always tell my lab that I look forward to the ACIR write ups and especially the cartoons! Thank you for helping to disseminate complex science!

🚨Now online at European Journal of Cancer
👉Health-related quality of life analysis from the ASCENT trial
#SybilleLoibl Sara Tolaney #MartinePiccart Mafalda Oliveira Hope Rugo Aditya Bardia, MD Javier Cortes MD PhD
OncoAlert #bcsm #TNBC #HRQoL #SacituzumabGovitecan
sciencedirect.com/science/articl…

Junior faculty looking for research funding in oncology in solid tumors: Consider applying to the Gilead Research Scholars Program

Each award is $180K (2 yr period)

Must be w/i 7 yrs of faculty appt

Application Deadline: 1/10/2023

researchscholars.gilead.com/en/solid_tumor…

Gilead Sciences

LIVE at Athenian Onology Congress🇬🇷 #3rdAOC
Paolo Tarantino 🇮🇹

HER2⃣low is NOT🚫a new subtype of #BreastCancer
It's a targetable🎯subgroup which T-DXd is a new standard of care option‼️

✅Better HER2⃣assays could expand the targetable pie-chart of HER2

✅Expanding ADC benefits

So rewarding to partner with Brittany Bychkovsky, MD and Dana-Farber’s Breast Oncology Center to publish this paper and start answering some questions about CHEK2 and cancer risks. JAMA Oncology

Beca ⁦SEOM⁩ de Estancia 12 meses en ⁦Dana-Farber’s Breast Oncology Center⁩

Muchas felicidades Dra. Olga Martinez-Saez ⁦Olga Martínez-Sáez⁩

⁦Hospital CLÍNIC⁩ ⁦IDIBAPS⁩ ⁦Universitat de Barcelona⁩

#BreastCancer experts Sara Tolaney and Elahe Salehi DNP provide essential guidance to improve #adherence and keep patients benefiting from #CDK4 /6 inhibitors in this new #MedEd video activity bit.ly/3z4jnQT

Thank you Boston 25 News for talking to Ann Partridge MD, MPH about Dana-Farber's Young and Strong Program, which supports young breast cancer patients like Christine Danielson. 'The amount of outreach and support . . . has been nothing short of amazing,' said Danielson.

Thanks OOFOS for your positive energy, investment and dedication♥️ Your efforts are making a difference in #breastcancer research.

Ambrx announced that it will suspend development of the anti-HER2 ADC #ARX788 . The drug had shown an ORR of 65% & mPFS of 17 months in a phase 1 trial for patients with pretreated HER2+ MBC. Sad news for a promising drug.
biospace.com/article/ambryx…

Congrats Olga Martínez-Sáez !
We're excited to get to work with you Dana-Farber’s Breast Oncology Center!

🤔Are you still confused about the new #HER2 low categorization? 🤔
Then check out➡️this The Washington Post article with Dr. Sara Tolaney (@stolaney1), which explains the importance of the new #HER2 categorization for #MetastaticBreastCancer treatment. #bcsm
washingtonpost.com/creativegroup/…